Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 ...

The ruling makes clear that the FDA lacks the legal authority to regulate LDTs, and observers suggest it could also call into question its authority in other areas.

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Life-saving research in rare cancers would be encouraged under a proposed law aiming to improve access to clinical trials in the UK, according to a Labour MP. Scott Arthur said his Rare Cancers Bill ...

Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused ...

We have also added the hedge fund sentiment for each stock which was sourced from Insider Monkey’s database. Why are we ...

That was followed in June 2022 by the FDA's granting of Orphan Drug designation to rencofilstat for the treatment ... These patients will be added to Hepion's existing safety database. The Company ...

ClinVar, another significant database, offers a detailed information on genomic ... enabling the repurposing of existing medication for orphan diseases, accelerating drug development and reducing ...

Narsoplimab has orphan drug designation from EMA for treatment in hematopoietic stem cell transplantation. In preparation with our efforts on BLA and MAA submissions, two manuscripts authored by ...